Latest nasopharyngeal cancer Stories

2014-07-01 16:25:09

LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/drug_discovery/nasopharyngeal_cancer_global_clinical_trials_review_h1_2014.html Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Nasopharyngeal...

2014-03-20 20:21:55

MARKHAM, ON, March 20, 2014 /PRNewswire/ - A Markham, Ontario-based company has developed a specialized test which screens for nasopharyngeal cancer. (Photo: http://photos.prnewswire.com/prnh/20140320/TO592) Nasopharyngeal cancer, known as NPC, is a rare but deadly disease. It is global in scope, and individuals with a Hong Kong, Southeast Asian, Inuit, North African, or Middle Eastern background have a higher risk for NPC. These individuals may benefit from this early...

2009-10-08 08:23:22

An increase in cases of a rare type of head and neck cancer appears to be linked to HPV, or human papillomavirus, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. The study looked at patients with nasopharyngeal cancer, a tumor that grows behind the nose and at the top of the throat, above the tonsils. This rare cancer occurs in less than 1 of every 100,000 Americans. "Though rare, this is the first report of nasopharyngeal cancer being...

2009-04-29 06:00:00

- Malaysian Ministry of Health provides grant to develop blood-based diagnostic tests for liver cancer, Hepatitis B and nasopharyngeal cancer - TORONTO, April 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it will undertake a two-year joint project to develop blood-based diagnostic tests for liver cancer, Hepatitis B...

2008-07-14 09:00:14

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva(R)) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin(R)) in models of breast cancer. These preclinical results were published in the July issue of the...

Word of the Day
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.